Yes. Creative Biolabs can compare viral platforms according to genome capacity, tumor tropism, replication behavior, transgene arming feasibility, immune-stimulation profile, delivery route, available tumor models, manufacturability considerations, and safety requirements. The goal is to narrow the program to a platform that fits the biological question and the next development milestone, not simply to select the most familiar virus type.

Yes. Early projects can begin with a disease area, mechanism hypothesis, plasmid design, genome sequence, proposed payload, target antigen, or exploratory data package. When materials are limited, the first step is usually a feasibility and evidence-planning review that defines the minimum information needed for construction, validation, or route selection.

Helpful inputs include the virus type or intended platform, construct map or sequence, payload design, available plasmids or viral stocks, target indication, preferred cell or animal models, previous assay results, biosafety requirements, expected deliverables, timeline, and whether the work is intended for screening, mechanism confirmation, preclinical planning, or CMC-oriented preparation.

Yes. Projects may involve unarmed viruses, viruses carrying cytokines, chemokines, checkpoint-related payloads, antibodies, enzymes, reporter genes, tumor antigens, or other functional cassettes. Engineering decisions can also include promoter selection, miRNA detargeting, attenuation logic, tropism adjustment, and safety-control design, depending on platform compatibility and study intent.

Yes. Candidate comparison can be configured as a harmonized screening package using standardized MOI, time-course, tumor cell panels, normal-cell counterscreens, replication kinetics, payload expression assays, cytotoxicity readouts, and manufacturability-related observations. A shared control framework makes ranking more interpretable across constructs.

Yes. If a client already has plasmids, viral stock, infected cell lysate, purified virus, a producer cell line, or previous characterization data, the work can start from verification, rescue, propagation, purification, analytical confirmation, or functional testing rather than redesign. Intake review helps determine which existing materials are usable and which controls should be added.

Cell-based assays help define infection, replication, killing, payload expression, immune activation, and selectivity. These results guide model choice, route, dose, schedule, biodistribution, shedding, tumor response, immune profiling, and safety endpoints for in vivo work. The most efficient programs use early validation data to avoid poorly matched animal studies.

Yes. Depending on the mechanism and indication, validation can include 2D tumor cell panels, spheroids, organoids, stromal co-cultures, immune co-cultures, PBMC-based assays, engineered immune-cell systems, or disease-specific model formats. These systems can help assess tumor penetration, immune activation, payload function, and model relevance before animal expansion.

Go/no-go criteria are defined around the project objective. For early screening, the key criteria may be replication, killing, expression, or selectivity. For translational work, criteria may include biodistribution, immune infiltration, tumor growth delay, survival, shedding, tolerability, potency, or analytical comparability. Creative Biolabs can help define thresholds before experiments begin.

Yes. Delivery-related work can consider intratumoral, systemic, regional, carrier-based, or formulation-supported approaches. Planning may address local retention, systemic exposure, tumor penetration, shielding from neutralization, storage conditions, handling, compatibility with downstream assays, and confirmatory tests for route feasibility.

CMC and QC planning should be considered before the program becomes dependent on non-comparable batches or poorly documented methods. Early attention to seed stock, infectious titer, genome copy number, identity, purity, residuals, potency, stability, and batch records can make later optimization and external transfer more efficient.

Outputs depend on scope, but may include design rationales, construction records, protocols, batch information, analyzed datasets, growth curves, dose-response plots, replication kinetics, cytokine or immune profiling summaries, biodistribution or histology summaries, QC notes, interpretive reports, risk registers, and recommended next-step service routing.